Nordström P, Bergman J, Ballin M, et al. - This study was undertaken to determine if use of bone‐specific drugs (BSDs) is associated with an increased risk of osteonecrosis of sites other than the jaw in a Swedish nationwide cohort. Two studies, a cohort study and a case–control study, were performed using registry data for all those who lived in Sweden on December 31, 2005, and were at that time 50 years of age or older (n = 3,523,912). According to findings, use of BSDs was linked to an increased risk of osteonecrosis of sites other than the jaw. Higher risks were associated with more potent drugs and higher doses of more potent drugs. In patients with a hip fracture that was not operated with prosthesis, the highest absolute additional risk related to use of BSD was found. Osteonecrosis risk decreased with longer time between the hip fracture and the begin of treatment with BSD. The findings could not be tested for causality despite the few cases identified from clinical trials.